Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Shares Outstanding (2016 - 2025)

Orthofix Medical's Shares Outstanding history spans 17 years, with the latest figure at $39.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 3.5% year-over-year to $39.8 million, compared with a TTM value of $39.8 million through Dec 2025, up 3.5%, and an annual FY2025 reading of $39.8 million, up 3.5% over the prior year.
  • Shares Outstanding for Q4 2025 was $39.8 million at Orthofix Medical, up from $39.5 million in the prior quarter.
  • The five-year high for Shares Outstanding was $39.8 million in Q4 2025, with the low at $2.0 million in Q3 2021.
  • Average Shares Outstanding over 5 years is $29.9 million, with a median of $36.7 million recorded in 2023.
  • Biggest YoY gain for Shares Outstanding was 102026.24% in 2021; the steepest drop was 89.75% in 2021.
  • Tracing OFIX's Shares Outstanding over 5 years: stood at $19.8 million in 2021, then grew by 1.64% to $20.2 million in 2022, then soared by 84.33% to $37.2 million in 2023, then grew by 3.55% to $38.5 million in 2024, then increased by 3.5% to $39.8 million in 2025.
  • Per Business Quant, the three most recent readings for OFIX's Shares Outstanding are $39.8 million (Q4 2025), $39.5 million (Q3 2025), and $39.5 million (Q2 2025).